JP2024026132A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024026132A5 JP2024026132A5 JP2023197481A JP2023197481A JP2024026132A5 JP 2024026132 A5 JP2024026132 A5 JP 2024026132A5 JP 2023197481 A JP2023197481 A JP 2023197481A JP 2023197481 A JP2023197481 A JP 2023197481A JP 2024026132 A5 JP2024026132 A5 JP 2024026132A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- cancer
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 241000235648 Pichia Species 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Claims (16)
- 抗体軽鎖可変領域と、抗体重鎖可変領域と、を含む抗Ｂ７－Ｈ４抗体又はその抗原結合断片であって、
前記抗体軽鎖可変領域は、それぞれＳＥＱ ＩＤ ＮＯ：６、ＳＥＱ ＩＤ ＮＯ：７及びＳＥＱ ＩＤ ＮＯ：８に示されるＬＣＤＲ１、ＬＣＤＲ２及びＬＣＤＲ３を含み、前記抗体重鎖可変領域は、それぞれＳＥＱ ＩＤ ＮＯ：３、ＳＥＱ ＩＤ ＮＯ：４及びＳＥＱ ＩＤ ＮＯ：５に示されるＨＣＤＲ１、ＨＣＤＲ２及びＨＣＤＲ３を含み、又は、
前記抗体軽鎖可変領域は、それぞれＳＥＱ ＩＤ ＮＯ：７０、ＳＥＱ ＩＤ ＮＯ：７１及びＳＥＱ ＩＤ ＮＯ：７２に示されるＬＣＤＲ１、ＬＣＤＲ２及びＬＣＤＲ３を含み、前記抗体重鎖可変領域は、それぞれＳＥＱ ＩＤ ＮＯ：６７、ＳＥＱ ＩＤ ＮＯ：６８及びＳＥＱ ＩＤ ＮＯ：６９に示されるＨＣＤＲ１、ＨＣＤＲ２及びＨＣＤＲ３を含む、
抗Ｂ７－Ｈ４抗体又はその抗原結合断片。 - 前記抗体は、マウス抗体、キメラ抗体、ヒト抗体及びヒト化抗体から選択される、請求項１に記載の抗Ｂ７－Ｈ４抗体又はその抗原結合断片。
- 前記ヒト化抗体の重鎖可変領域は、
ヒトＩｇＧ１、ＩｇＧ２、ＩｇＧ３又はＩｇＧ４又はその変異体の重鎖定常領域をさらに含み、又は、
ヒトＩｇＧ１、ＩｇＧ２又はＩｇＧ４重鎖定常領域をさらに含み、又は、
アミノ酸変異によりＡＤＣＣ毒性を増強させたＩｇＧ１重鎖定常領域を含む、請求項２に記載の抗Ｂ７－Ｈ４抗体又はその抗原結合断片。 - 前記ヒト化抗体は、（１）ＳＥＱ ＩＤ ＮＯ：７６の軽鎖可変領域及びＳＥＱ ＩＤ ＮＯ：７５の重鎖可変領域、又は（２）ＳＥＱ ＩＤ ＮＯ：８２の軽鎖可変領域及びＳＥＱ ＩＤ ＮＯ：８１の重鎖可変領域を含む、請求項２に記載の抗Ｂ７－Ｈ４抗体又はその抗原結合断片。
- 前記ヒト化抗体は、（１）ＳＥＱ ＩＤ ＮＯ：８４の軽鎖及びＳＥＱ ＩＤ ＮＯ：８３の重鎖、又は（２）ＳＥＱ ＩＤ ＮＯ：９０の軽鎖及びＳＥＱ ＩＤ ＮＯ：８９の重鎖を含む、請求項２に記載の抗Ｂ７－Ｈ４抗体又はその抗原結合断片。
- 請求項１～５のいずれか１項に記載の抗体又はその抗原結合断片をコードするＤＮＡ分子。
- 請求項６に記載のＤＮＡ分子を含む発現ベクター。
- 請求項７に記載の発現ベクターを導入又は含有する宿主細胞。
- 細菌、酵母菌又は哺乳動物細胞であることを特徴とする、請求項８に記載の宿主細胞。
- 大腸菌、ピキア酵母、チャイニーズハムスター卵巣（ＣＨＯ）細胞又はヒト胎児腎（ＨＥＫ）２９３細胞であることを特徴とする、請求項９に記載の宿主細胞。
- 請求項８～１０のいずれか１項に記載の宿主細胞を培養し、培養物から抗体を分離し、抗体を精製することを含む、抗体を産生する方法。
- 請求項５に記載の抗Ｂ７－Ｈ４抗体又はその抗原結合断片及び薬学的に許容される賦形剤、希釈剤又は担体を含有する、医薬組成物。
- 請求項１～５のいずれか１項に記載の抗Ｂ７－Ｈ４抗体又はその抗原結合断片を含む、検出試薬。
- 請求項１～５のいずれか１項に記載の抗Ｂ７－Ｈ４抗体又はその抗原結合断片を含む、診断剤。
- Ｂ７－Ｈ４媒介性疾患又は症状を治療又は予防するための薬物の製造における請求項１～５のいずれか１項に記載の抗Ｂ７－Ｈ４抗体又はその抗原結合断片、又は請求項１２に記載の医薬組成物の使用。
- 前記疾患は、癌であり、又は、
Ｂ７－Ｈ４を発現する癌であり、又は、
卵巣癌、前立腺癌、膵臓癌、腎臓癌、肺癌、肝臓癌、胃癌、結腸癌、膀胱癌、食道癌、子宮頸癌、胆嚢癌、膠芽腫及び黒色腫である、請求項１５に記載の使用。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810142118 | 2018-02-11 | ||
| CN201810142118.6 | 2018-02-11 | ||
| PCT/CN2019/074397 WO2019154315A1 (zh) | 2018-02-11 | 2019-02-01 | 抗b7-h4抗体、其抗原结合片段及其医药用途 |
| JP2020542138A JP7393337B2 (ja) | 2018-02-11 | 2019-02-01 | 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542138A Division JP7393337B2 (ja) | 2018-02-11 | 2019-02-01 | 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024026132A JP2024026132A (ja) | 2024-02-28 |
| JP2024026132A5 true JP2024026132A5 (ja) | 2024-03-15 |
Family
ID=67548182
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542138A Active JP7393337B2 (ja) | 2018-02-11 | 2019-02-01 | 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途 |
| JP2023197481A Pending JP2024026132A (ja) | 2018-02-11 | 2023-11-21 | 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542138A Active JP7393337B2 (ja) | 2018-02-11 | 2019-02-01 | 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11472882B2 (ja) |
| EP (1) | EP3753951A4 (ja) |
| JP (2) | JP7393337B2 (ja) |
| KR (1) | KR20200119846A (ja) |
| CN (2) | CN116693686A (ja) |
| AU (1) | AU2019218319A1 (ja) |
| BR (1) | BR112020015736A2 (ja) |
| CA (1) | CA3089246A1 (ja) |
| MX (1) | MX2020008181A (ja) |
| TW (1) | TWI823895B (ja) |
| WO (1) | WO2019154315A1 (ja) |
| ZA (1) | ZA202004701B (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3142641A1 (en) * | 2019-06-06 | 2020-12-10 | Shanghai Hansoh Biomedical Co., Ltd. | Anti-b7-h4 antibody-drug conjugate and medicinal use thereof |
| AU2021327599A1 (en) * | 2020-08-18 | 2024-02-15 | Abl Bio, Inc. | Anti-b7-h4/anti-4-1bb bispecific antibodies and use thereof |
| MX2023008000A (es) | 2021-01-04 | 2023-07-13 | Mersana Therapeutics Inc | Conjugados de anticuerpo dirigido a b7-h4 y farmaco, y metodos de uso de los mismos. |
| CA3207652A1 (en) | 2021-03-26 | 2022-09-29 | Stephanie Cornen | Cytokine anchors for nkp46-binding nk cell engager proteins |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258662A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
| WO2023283345A1 (en) * | 2021-07-07 | 2023-01-12 | Incyte Corporation | Anti-b7-h4 antibodies and uses thereof |
| US20230312724A1 (en) * | 2021-12-01 | 2023-10-05 | Kadmon Corporation, Llc | B7-H4 Antibodies and Anti-B7-H4 Antibody/IL-15 Fusion Proteins |
| US20230348588A1 (en) * | 2021-12-23 | 2023-11-02 | Prothena Biosciences Limited | Antibodies recognizing sortilin |
| TW202340255A (zh) * | 2022-03-30 | 2023-10-16 | 大陸商映恩生物製藥（蘇州）有限公司 | B7h4抗體藥物偶聯物及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858710B2 (en) * | 1998-12-17 | 2005-02-22 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| US20030091580A1 (en) * | 2001-06-18 | 2003-05-15 | Mitcham Jennifer L. | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| BRPI0818963A2 (pt) | 2007-11-30 | 2015-05-05 | Bristol Myers Squibb Co | Conjugado anticorpo-molécula parceira e método para tratar câncer em um indivíduo |
| JP6120848B2 (ja) | 2011-08-15 | 2017-04-26 | メディミューン，エルエルシー | 抗ｂ７−ｈ４抗体およびその使用 |
| EP2934576A1 (en) | 2012-12-19 | 2015-10-28 | The Johns Hopkins University | Anti-human b7-h4 antibodies and their uses |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| EP3299391B1 (en) | 2013-03-14 | 2019-12-04 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
| CN103981150B (zh) | 2014-03-28 | 2016-06-01 | 苏州大学 | 抗人b7-h4单克隆抗体及其制备和应用 |
| CN106804108B (zh) * | 2014-09-12 | 2021-08-10 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
| AU2016243126A1 (en) * | 2015-03-27 | 2017-11-02 | University Of Southern California | CAR T-cells for the treatment of B7-H4 expressing solid tumors |
| CN107299085B (zh) | 2017-05-26 | 2020-09-29 | 广东医科大学 | 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用 |
| CN111971308A (zh) * | 2018-03-02 | 2020-11-20 | 戊瑞治疗有限公司 | B7-h4抗体及其使用方法 |
| KR102227515B1 (ko) | 2018-12-18 | 2021-03-12 | 주식회사 포스코 | 제올라이트 및 그 제조방법 |
-
2019
- 2019-02-01 CN CN202310820681.5A patent/CN116693686A/zh active Pending
- 2019-02-01 AU AU2019218319A patent/AU2019218319A1/en active Pending
- 2019-02-01 JP JP2020542138A patent/JP7393337B2/ja active Active
- 2019-02-01 CN CN201980001361.9A patent/CN110366560B/zh active Active
- 2019-02-01 CA CA3089246A patent/CA3089246A1/en active Pending
- 2019-02-01 US US16/967,016 patent/US11472882B2/en active Active
- 2019-02-01 EP EP19750949.0A patent/EP3753951A4/en active Pending
- 2019-02-01 MX MX2020008181A patent/MX2020008181A/es unknown
- 2019-02-01 BR BR112020015736-8A patent/BR112020015736A2/pt unknown
- 2019-02-01 KR KR1020207026012A patent/KR20200119846A/ko unknown
- 2019-02-01 WO PCT/CN2019/074397 patent/WO2019154315A1/zh unknown
- 2019-02-11 TW TW108104453A patent/TWI823895B/zh active
-
2020
- 2020-07-29 ZA ZA2020/04701A patent/ZA202004701B/en unknown
-
2023
- 2023-11-21 JP JP2023197481A patent/JP2024026132A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024026132A5 (ja) | ||
| EP3368572B1 (en) | Anti-pd-1 antibodies and compositions | |
| CA2987118C (en) | A pdl-1 antibody, pharmaceutical composition thereof and use thereof | |
| JP6205410B2 (ja) | Ｓｔ２抗原結合タンパク質 | |
| TWI708788B (zh) | 雙特異性抗體 | |
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| CA3034849A1 (en) | Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof | |
| RU2020127196A (ru) | Антитело против 4-1bb, его антигенсвязывающий фрагмент и его медицинское применение | |
| WO2014194274A2 (en) | Oncostatin m receptor antigen binding proteins | |
| AU2017292752B2 (en) | Antibodies with low immunogenicity and uses thereof | |
| US20210189003A1 (en) | De-immunised anti-erbb3 antibodies | |
| JP2020522280A5 (ja) | ||
| JP2020522281A5 (ja) | ||
| US20220119545A1 (en) | Cdcp1-targeted therapies | |
| US11655300B2 (en) | Colony stimulating factor 1 receptor (CSF1R) antibodies and immunoconjugates thereof | |
| JP2019509714A5 (ja) | ||
| US20210284734A1 (en) | Anti-pd-1 antibodies and compositions | |
| US20210317216A1 (en) | Anti-flt3 antibodies and compositions | |
| WO2023025194A1 (zh) | Fap/cd40结合分子及其医药用途 | |
| RU2020124155A (ru) | Антитело к b7-h4, его антигенсвязывающий фрагмент и его фармацевтическое применение | |
| RU2021111145A (ru) | Анти-cd73 антитело, его антигенсвязывающий фрагмент и их применение | |
| JP2022545834A (ja) | 抗ｃｄ２０抗体、抗ｃｄ３７抗体、およびこれらの混合物 | |
| RU2021116840A (ru) | Антитело против cd40, его антигенсвязывающий фрагмент и фармацевтическое применение | |
| CN118047871A (zh) | 一种靶向FRα的抗体或其抗原结合片段及其应用 | |
| RU2022100311A (ru) | Антитело к BCMA, его антиген-связывающий фрагмент и их медицинское применение |